Systems Challenges of Hepatic Carcinomas: A Review

Bodzin, 2015, Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome, World J Hepatol, 7, 1157, 10.4254/wjh.v7.i9.1157 Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN, Int J Cancer, 136, E359, 10.1002/ijc.29210 Fares, 2013, Epidemiology, natural history, and risk factors of hepatocellular carcinoma, Rev Prat, 63, 216 Shariff, 2009, Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics, Expert Rev Gastroenterol Hepatol, 3, 353, 10.1586/egh.09.35 Kim, 2012, Epidemiology and surveillance of hepatocellular carcinoma, Liver Cancer, 1, 2, 10.1159/000339016 Wang, 2015, Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma, Asian Pac J Cancer Prev, 16, 3595, 10.7314/APJCP.2015.16.9.3595 Dzivenu, 2003 Finn, 2012, Immuno-oncology: understanding the function and dysfunction of the immune system in cancer, Ann Oncol, 23, viii6, 10.1093/annonc/mds256 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Sloan, 2007 Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Zamarron, 2011, Dual roles of immune cells and their factors in cancer development and progression, Int J Biol Sci, 7, 651, 10.7150/ijbs.7.651 Sachdeva, 2015, Immunology of hepatocellular carcinoma, World J Hepatol, 7, 2080, 10.4254/wjh.v7.i17.2080 Boyman, 2012, The role of interleukin-2 during homeostasis and activation of the immune system, Nat Rev Immunol, 12, 180, 10.1038/nri3156 Seruga, 2008, Cytokines and their relationship to the symptoms and outcome of cancer, Nat Rev Cancer, 8, 887, 10.1038/nrc2507 Wu, 2016, Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation, Sci Rep, 6, 1 Budhu, 2006, The role of cytokines in hepatocellular carcinoma, J Leukoc Biol, 80, 1197, 10.1189/jlb.0506297 Qin, 2012, Inflamatoria immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma, Cancer Microenviron, 5, 203, 10.1007/s12307-012-0111-1 Tanaka, 2003, Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan, J Infect Dis, 187, 1822, 10.1086/375248 Hong, 2015, Immunotherapy for hepatocellular carcinoma: from basic research to clinical use, World J Hepatol, 7, 980, 10.4254/wjh.v7.i7.980 Whittaker, 2010, The role of signaling pathways in the development and treatment of hepatocellular carcinoma, Oncogene, 29, 4989, 10.1038/onc.2010.236 Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002/hep.22506 Takami, 2007, Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis, Cancer Res, 67, 9844, 10.1158/0008-5472.CAN-07-1905 Comoglio, 2008, Drug development of MET inhibitors: targeting oncogene addiction and expedience, Nat Rev Drug Discov, 7, 504, 10.1038/nrd2530 Osipo, 2006, Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC, Cancer Biol Ther, 5, 238, 10.4161/cbt.5.2.2566 Liang, 2015, Chemokines and their receptors play important roles in the development of hepatocellular carcinoma, World J Hepatol, 7, 1390, 10.4254/wjh.v7.i10.1390 Sutton, 2007, Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion, Mol Cancer Res, 5, 21, 10.1158/1541-7786.MCR-06-0103 Liu, 2008, Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells, Cell Mol Immunol, 5, 373, 10.1038/cmi.2008.46 Fu, 2013, Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma, Hepatology, 58, 139, 10.1002/hep.26054 Cabrera, 2013, Another armed CD4 (+) T cell ready to battle hepatocellular carcinoma, Hepatology, 58, 1, 10.1002/hep.26377 Ormandy, 2005, Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma, Cancer Res, 65, 2457, 10.1158/0008-5472.CAN-04-3232 Shen, 2014, Increased circulating Lin (−/low) CD33 (+) HLA-DR (−) myeloid-derived suppressor cells in hepatocellular carcinoma patients, Hepatol Res, 44, 639, 10.1111/hepr.12167 Qin, 2012, Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma, Cancer Microenviron, 5, 203, 10.1007/s12307-012-0111-1 Chew, 2012, Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma, Gut, 61, 427, 10.1136/gutjnl-2011-300509 Bray, 2011, Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients, Clin Dev Immunol, 249281, 1, 10.1155/2011/249281 Kakumu, 2000, Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection, J Gastroenterol Hepatol, 15, 431, 10.1046/j.1440-1746.2000.02161.x Tada, 2012, Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma, Int J Oncol, 41, 1601, 10.3892/ijo.2012.1626 Bruix, 2004, Focus on hepatocellular carcinoma, Cancer Cell, 5, 215, 10.1016/S1535-6108(04)00058-3 Villanueva, 2007, Genomics and signaling pathways involved in the pathogenesis of HCC, Semin Liver Dis, 27, 55, 10.1055/s-2006-960171 Kancherla, 2018, Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma, Front Genet, 9, 1 Mao, 2017, Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis, Oncotarget, 8, 26185, 10.18632/oncotarget.15428 Andrade, 2018, TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma, Fam Cancer, 17, 119, 10.1007/s10689-017-9998-5 Thorgeirsson, 2002, Molecular pathogenesis of human hepatocellular carcinoma, Nat Genet, 31, 339, 10.1038/ng0802-339 Grisham, 2002, Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma, 269 Buendia, 2000, Genetics of hepatocellular carcinoma, Semin Cancer Biol, 10, 185, 10.1006/scbi.2000.0319 Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038/nrc1934 Dhanasekaran, 2012, Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics, Hepatic Med: Evid Res, 4, 19 Murakami, 2005, Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas, Gut, 54, 1162, 10.1136/gut.2004.054452 Tarn, 2001, Hepatitis B virus X protein differentially activates RASRAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes, J Biol Chem, 276, 34671, 10.1074/jbc.M104105200 Feitelson, 2002, Genetic mechanisms of hepatocarcinogenesis, Oncogene, 21, 2593, 10.1038/sj.onc.1205434 Macdonald, 2003, The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling, J Biol Chem, 278, 17775, 10.1074/jbc.M210900200 Majumder, 2001, Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner, J Virol, 75, 1401, 10.1128/JVI.75.3.1401-1407.2001 Roberts, 2005, Hepatocellular carcinoma: molecular pathways and new therapeutic targets, Semin Liver Dis, 25, 212, 10.1055/s-2005-871200 Breuhahn, 2006, Dysregulation of growth factor signaling in human hepatocellular carcinoma, Oncogene, 25, 3787, 10.1038/sj.onc.1209556 Branda, 2006, Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma, Hepatology, 43, 891, 10.1002/hep.21196 de La Coste, 1998, Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc Natl Acad Sci U S A, 95, 8847, 10.1073/pnas.95.15.8847 Ishizaki, 2004, Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas, Int J Oncol, 24, 1077 Merle, 2004, Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma, Gastroenterology, 127, 1110, 10.1053/j.gastro.2004.07.009 Wodarz, 1998, Mechanisms of Wnt signaling in development, Annu Rev Cell Dev Biol, 14, 59, 10.1146/annurev.cellbio.14.1.59 Tanaka, 2006, Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients, Oncogene, 25, 2950, 10.1038/sj.onc.1209311 Lee, 2005, PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas, Oncogene, 24, 1477, 10.1038/sj.onc.1208304 Sabatini, 2006, mTOR and cancer: insights into a complex relationship, Nat Rev Cancer, 6, 729, 10.1038/nrc1974 Xiao, 2018, Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: recent progress and future prospects, Oncol Lett Mohamed, 2017, MicroRNAs and clinical implications in hepatocellular carcinoma, World J Hepatol, 9, 1001, 10.4254/wjh.v9.i23.1001 Zhou, 2011, Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma, J Clin Oncol, 29, 4781, 10.1200/JCO.2011.38.2697 Shen, 2016, Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies, Hepatoma Res, 2, 151, 10.20517/2394-5079.2015.66 Gong, 2014, Emerging role of microRNA in hepatocellular carcinoma, Oncol Lett, 9, 1027, 10.3892/ol.2014.2816 Lu, 2017, A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis, Oncotarget, 8, 10.18632/oncotarget.14452 Chen, 2016, Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinic pathological and in silico study, Onco Targets Ther, 9, 5163, 10.2147/OTT.S108828 Sartorius, 2018, The biological and diagnostic role of miRNA's in hepatocellular carcinoma, Front Biosci, 23, 1701, 10.2741/4668 Lee, 2015, Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk, Sci Rep, 5, 17030, 10.1038/srep17030 Vivekanandan, 2008, High-dimensional biology to comprehend hepatocellular carcinoma, Expert Rev Proteomics, 5, 45, 10.1586/14789450.5.1.45 Chauhan, 2016, Tissue- and serum-associated biomarkers of hepatocellular carcinoma, Biomark Cancer, 8, 37 Lou, 2017, Biomarkers for hepatocellular carcinoma, Biomark Cancer, 1 Berretta, 2017, Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications, Oncotarget, 8, 14192, 10.18632/oncotarget.13929 Clark, 2016, Serum markers for hepatocellular carcinoma, Clin Liver Dis, 8, 29, 10.1002/cld.565 Ye, 2003, Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervise machine learning, Nat Med, 9, 416, 10.1038/nm843 Chauhan, 2016, Tissue- and serum-associated biomarkers of hepatocellular carcinoma, Biomark Cancer, 8, 37 Mann, 2007, Prognostic molecular markers in hepatocellular carcinoma: a systematic review, Eur J Cancer, 43, 979, 10.1016/j.ejca.2007.01.004 Daniele, 2004, Alphafetoprotein and ultrasonography screening for hepatocellular carcinoma, Gastroenterology, 127, 108, 10.1053/j.gastro.2004.09.023 Camaggi, 2010, Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification, Clin Chem Lab Med, 48, 1319, 10.1515/cclm.2010.248 Kragh-Hansen, 2002, Practical aspects of the ligand-binding and enzymatic properties of human serum albumin, Biol Pharm Bull, 25, 695, 10.1248/bpb.25.695 Mathé, 2002, Survey and summary: current methods of gene prediction, their strengths and weaknesses, Nucleic Acids Res, 30, 4103, 10.1093/nar/gkf543 Maji, 2013, Progress in gene prediction: principles and challenges, Curr Bioinform, 8, 1, 10.2174/1574893611308020011 Iddamalgoda, 2016, Data mining and pattern recognition models for identifying inherited diseases: challenges and implications, Front Genet, 10, 136 Lafaro, 2015, Epidemiology of hepatocellular carcinoma, Surg Oncol Clin N Am, 24, 1, 10.1016/j.soc.2014.09.001 Cho, 2007, Cancer biomarker discovery: the contribution of “omics”, BIOforum Eur, 11, 35 Lee, 2011, Systems biology approaches to decoding the genome of liver cancer, Cancer Res Treat, 43, 205, 10.4143/crt.2011.43.4.205 Malaguarnera, 2014, Hepatocellular carcinoma markers in the omics era: the glycomic analysis, Hepatobiliary Surg Nutr, 3, 407 Wu, 2017, Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib, Cancer Lett, 388, 73, 10.1016/j.canlet.2016.11.032 Zucman-Rossi, 2007, Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies, Pharmacogenomics, 8, 997, 10.2217/14622416.8.8.997 Paolillo, 2016, Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine, Scand J Clin Lab Invest Suppl, 245, S84, 10.1080/00365513.2016.1210331 Ma, 2017, Non-alcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes, FEBS J Lou, 2017, Biomarkers for hepatocellular carcinoma, Biomark Cancer, 10.1177/1179299X16684640